Geode Capital Management LLC Has $4.95 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Geode Capital Management LLC increased its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 3.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 477,351 shares of the biotechnology company’s stock after buying an additional 14,575 shares during the quarter. Geode Capital Management LLC owned about 2.25% of Enanta Pharmaceuticals worth $4,946,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ENTA. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth $122,000. American Century Companies Inc. grew its stake in Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after buying an additional 7,287 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Enanta Pharmaceuticals by 65.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 18,003 shares in the last quarter. Erste Asset Management GmbH acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $1,243,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $903,000. Institutional investors own 94.99% of the company’s stock.

Insiders Place Their Bets

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares in the company, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 13.64% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ENTA shares. HC Wainwright decreased their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th. JMP Securities reissued a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, Robert W. Baird decreased their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Enanta Pharmaceuticals Stock Down 0.2 %

Shares of Enanta Pharmaceuticals stock opened at $5.58 on Friday. The stock has a market cap of $118.26 million, a price-to-earnings ratio of -1.02 and a beta of 0.56. Enanta Pharmaceuticals, Inc. has a twelve month low of $5.30 and a twelve month high of $17.80. The company’s fifty day moving average is $8.47 and its 200 day moving average is $11.23.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. During the same quarter last year, the firm posted ($1.33) EPS. The company’s quarterly revenue was down 22.8% on a year-over-year basis. As a group, equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.73 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.